WO2004065390A1 - Process and intermediates for the preparation of olanzapine - Google Patents

Process and intermediates for the preparation of olanzapine Download PDF

Info

Publication number
WO2004065390A1
WO2004065390A1 PCT/EP2004/000299 EP2004000299W WO2004065390A1 WO 2004065390 A1 WO2004065390 A1 WO 2004065390A1 EP 2004000299 W EP2004000299 W EP 2004000299W WO 2004065390 A1 WO2004065390 A1 WO 2004065390A1
Authority
WO
WIPO (PCT)
Prior art keywords
ml
ch
benzodiazepine
olanzapine
mmol
Prior art date
Application number
PCT/EP2004/000299
Other languages
French (fr)
Other versions
WO2004065390A8 (en
Inventor
Roman Lenarsic
Rok Zupet
Milena Benedik
Barbara Mohar
Anton Štimac
Original Assignee
Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE10301923.5 priority Critical
Priority to DE2003101923 priority patent/DE10301923B3/en
Application filed by Krka, Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D., Novo Mesto
Publication of WO2004065390A1 publication Critical patent/WO2004065390A1/en
Publication of WO2004065390A8 publication Critical patent/WO2004065390A8/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1,4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1,4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines

Abstract

The invention provides an improved process for preparing Olanzapine as well as intermediates therefor.

Description

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE

The invention belongs to the field of organic chemistry and relates to a new process and intermediates for the manufacture of a compound having the following formula I :

i.e. 2-methyl-4- (4-met

Figure imgf000002_0001
lOJf-thieno [2 , 3 -b] - [1, 5] benzodiazepine (hereinafter referred to by its generic name " Olanzapine" ) .

Olanzapine is a serotonin (5-HT2) and dopamine (O1/O2) receptor antagonist with anticholinergic activity. It is useful in treat- ing psychotic conditions such as schizophrenia, schizophreniform disorders, acute mania, states of mild anxiety and psychosis.

Heretofore, -only a few processes for the manufacture of Olanzapine have become known.

British patent GB 1,533,235 discloses a series of thieno[l,5]- benzodiazepine derivatives which are represented by the following generic formula:

Figure imgf000002_0002
wherein R and R represent various substituents, e.g. hydrogen, Rc represents amine substituents, e.g. 4-methylpiperazinyl, and T represents thiophene rings fused to the [1, 5] -benzodiazepine ring. An example of these derivatives is 2-methyl-10ff-thieno-

5 [2,3-b] [1, 5] benzodiazepine. These benzodiazepine derivatives are prepared by reacting a suitable precursor with an amine HR, so as

. to introduce the amine substituent R in the molecule.

Olanzapine and its synthesis were specifically disclosed in EP 0 10 454 436 Al . This application discloses two synthetic paths, which are depicted in scheme 1 below.

Both paths start with a Gewald reaction to form appropriately substituted 2-amino-thiophenes (a) . This type of reaction is 15 described in Chem. Ber. 1965, 98, 3571-3577; Chem. Ber. 1966, 99, 94-100. The second step involves the reaction of 2-amino- thiophene with 2-nitro-l-fluorobenzene (b) , to give a 2- (2- nitro-anilino) thiophene .

20 According to the first reaction path, this thiophene is then (c) reduced and cyclised to a benzodiazepine-4-amine hydrochloride . Replacement of the amine group by 1-methylpiperazine (d) leads to the desired Olanzapine.

25 In the second reaction path, the thiophene is catalytically hydrogenated to an amino-ester (e) , which is then transformed into an amino-amide (f) , and this amino-amide is subsequently cyclised (g) to give Olanzapine. This second approach requires chromatographic purification in each step, because the reactions

30 lack selectivity and because the products could not be obtained by precipitation. Scheme 1

Figure imgf000004_0001

In path 1, X is CN and in path 2, X is COOR, e.g. COOC2H5.

The reagents used in the respective steps of the reactions were as follows: (a) Et3N, DMF; (b) NaH, THF; (c) SnCl2, HCI; (d) DMSO, toluene; (e) H2, Pd/C, EtOH-EtOAc; (f) TiCl4, anisole; (g) TiCl4, anisole.

Besides the already mentioned requirement for chromatographic purification in early steps, causing high costs, low yields and substantial amounts of waste products, both paths have some further drawbacks. They provide only low yields, e.g. in the case of path 2 with X being COOC2H5 the yield of the first step is only 42...5 % as is reported in J. Heterocyclic Chem. 36, 1999, 333-345. Other drawbacks are that expensive compounds such as Pd have to be used as well as compounds that are toxic and not acceptable from an environmental point of view, like DMF, TiCl4 or SnCl2.

Thus, there exists a need for an improved process whic overcomes these drawbacks .

This object is surprisingly solved by the process for the manufacture of Olanzapine according to claims 1 to 5. The invention is also directed to the compounds according to claims 6 to 9 as well as to their use according to claim 10.

The process according to the invention for the manufacture of Olanzapine is characterized by converting a compound of the following formula II or a salt thereof

in which

Figure imgf000005_0001
( i) - Rl and R2 together form =CH-CH2-CH3, or

(ϋ) Rl and R2 are both H, or

(iii) Rl is H and R2 is -CH (R3) -CH2-CH3, wherein R3 is a leaving group, that can be eliminated together with Rl to result in Rl and R2 together forming =CH—CH —CH3 ,

to give Olanzapine or a salt thereof.

In the case of (i) the compound to be converted is the propylidene7diazepine of the following formula III:

or a salt thereof.

Figure imgf000006_0001

In the case of (ii) the compound to be converted is the diazepine of the following formula IV:

or a salt thereof.

Figure imgf000006_0002

In the case of (iii) the compound to be converted is the diazepine-derivative bearing a leaving group R3, as is shown in the following formula V:

Figure imgf000006_0003
or a salt thereof,

A preferred leaving group R3 is -OR . R4 can preferably be H, so that the leaving group R3 is preferably an alkohol group. In such a case the compound to be converted is the diazepine-alcohol of the following formula VI:

or a salt thereof

Figure imgf000007_0001

R4 can also be selected from the group of acyl, sulfonyl, pre- ferably trifluoroacetyl and methane sulfonyl, so that the leaving group R3 is an ester group, and the compound to be converted is the benzodiazepine-ester of the following formula VII:

Figure imgf000007_0002
or a salt thereof with R4 being preferably selected from the group of acyl, sulfonyl, and with R4 most preferably being trifluoroacetyl or methane sulfonyl.

In a particularly preferred embodiment of the process according to the invention, Rl and R2 together form =CH-CH2-CH3 and the conversion is performed by reacting the compound of formula II with a source of sulfur.

Particularly preferred embodiments of the process according to this invention are depicted in scheme 2, using the preferred precursors of the invention. Scheme 2

Figure imgf000008_0001

The reagents used in the respective steps are preferably as follows :

(a) Toluene, DMSO; (b) 1. LDA, THF, 2. (CF3CO)20, NaOH; (c) LDA, THF; (d)

Figure imgf000008_0002
or AHB or AH.

Besides the advantage of the high yields in the synthesis, the use of symmetrical intermediates according to the present invention is particularly advantageous because the possibility of obtaining undesired regioisomeres is exluded.

Thus, in a first preferred aspect of the invention Olanzapine can be produced in a reaction (e) of the propylidene- benzodiazepine of formula III with a source of sulphur [S] , preferably elementary sulphur or sodium poiysuiphide, which is usually base mediated. An appropriate base can be chosen among secondary or tertiary alkylamines of formula R NR R , in which R is H or R2, and R2 is a Cx- to C5-alkyl or cyclic amine such as morpholine, piperidine, piperazine or 1-methyl-piperazine . Preferably the base is chosen from tertiary alkyl-amines and the most preferable base is triethylamine . Acceptable solvents for the reaction are N-methyl- imidazole, dimethyl sulfoxide (DMSO) , C]_- to C5-aliphatic alcohols, alcoholamines, diols, polyols or mixtures thereof, preferably mixtures of dimethyl sulfoxide and alcohols . An appropriate reaction temperature range is from room temperature to the boiling point of the reaction mixture, preferably from 50°C to 150°C and most preferably is a reaction temperature of about 100°C.

The reaction can also be mediated with a salt AHB. This salt is composed of an acid AH and an amine B. The acid AH can be chosen among organic or anorganic acids . Preferred are organic car- boxylic or sulfonic acids, such as acetic acid,' trifluoroacetic acid, benzoic acid, 4-nitrobenoic acid, 4-chlorobenzoic acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzene- sulfonic acid or p-toluenesulfonic acid and most preferred are p-toluenesulfonic acid or methanesulfonic acid. The amine B can be chosen among secondary or tertiary aliphatic or aromatic amines. Preferred aromatic amines are pyridine picoline, luti- dine, quinoline, 2-methylquinoline or 1-methylimidazole and most preferred are pyridine or quinoline. Either part of the salt AHB can be polymer bound. Acceptable solvents for the reaction are high boiling point solvents. They can be hydrocarbons, ethers, esters, nitriles or alcohols or mixtures thereof. Preferred are aromatic ethers, esters, or nitriles, such as anisole, di- methoxybenzene, diphenyl ether, methyl benzoate, ethyl benzoate and benzonitrile and most preferred is benzonitrile . An appro- priate reaction temperature range is from 80°C to 220°C, preferably from 100°C to 180°C and most preferred is a reaction temperature of about 140°C.

The propylidene-benzodiazepine of formula III can preferably be synthesised via step (b) from the benzodiazepine of formula IV. In a preferred embodiment the benzodiazepine IV is firstly transformed to an alkali salt using strong bases such as alkali amides, alkali alkyls or alkali silazanes. Preferably lithium diisopropylamide (LDA) or butyl-lithium is used and most preferably lithium diisopropylamide is used. In an addition reaction of the alkali salt of the benzodiazepine IV to propionaldehyde .the benzodiazepine-alcoholate of the alcohol of formula VI is formed. The solvent for this reaction should be inert to strong bases and it is in particular chosen from ethers or aromatic hydrocarbons. Water miscible ethers are preferred, with the most preferable solvent being THF. Usual reaction temperatures range from -50 °C to room temperature, preferably from -30 °C to 0 °C. The benzodiazepine-alcoholate is than transformed to a benzodiazepine-ester of formula VII, in which R4 is in particular selected from the group of acyl or sulfonyl, preferably acetyl trifluoroacetyl or methane sulfonyl, with trifluoroacetyl being most preferred. The elimination of said ester group to produce the propylidene-benzodiazepine of formula III is accomplished by adding of an aqueous solution of alkali hydroxide salts such as lithium hydroxide, sodium hydroxide or potassium hydroxide and preferably is an aqueous solution of sodium hydroxide. When the organic solvent is immiscible with water, the reaction can be catalysed with quarternary ammonium salts, such as tetraalkylammonium chlorides, bromides, fluorides, hydroxides or cyanides, wherein "alkyl" represents groups having 1 to 8 carbon atoms. Preferably the reaction is catalysed with tetrabutylammonium bromide or hydroxide and most preferably with tetrabutylammonium bromide. It is most preferable that the sequence of these reactions is conducted as a one pot reaction.

Alternatively, the propylidene-diazepine of formula III can be prepared via step (d) starting from the benzodiazepine-alcohol of formula VI. The procedure is similar to the second part of step (b) . The benzodiazepine-alcohol is first transformed to a diazepine-ester of formula VII, in which R4 is in particular selected from the group of acyl or sulfonyl, preferably acetyl, trifluoroacetyl or methane sulfonyl, with trifluoroacetyl being most preferred. The elimination of the ester group to produce the propylidene-benzodiazepine of formula III is preferably carried out in a one or two phase solvent system. The organic solvent can be chosen from ethers, halogenated hydrocarbons or aromatic or aliphatic hydrocarbons and is preferably chosen from tetrahydrofuran, dichloromethane or toluene, with the most preferable solvent being tetrahydrofuran. The second solvent can be an aqueous solution of alkali hydroxide salts such as lithium hydroxide, sodium hydroxide, or potassium hydroxide and preferably is an aqueous solution of sodium hydroxide . In case of a two phase solvent system, the reaction can be catalysed with quarternary ammonium salts such as tetraalkylammonium chlorides, bromides, fluorides, hydroxides or cyanides, wherein "alkyl" represents groups having 1 to 8 carbon atoms. Preferably the reaction is catalysed with tetrabutylammonium bromide or hydroxide and most preferably with tetrabutylammonium bromide. It is most preferable that esterification and subsequent elimination of the resulting ester group are conducted as a one pot reac- tion.

The benzodiazepine-alcohol of formula VI is preferably obtained via step (c) in an addition reaction of an alkali salt of the benzodiazepine of formula IV to propionaldehyde . The alkali salt can be prepared using strong bases such as alkali amides, alkali alkyls or alkali silazanes. Preferably lithium diisopropylamide (LDA) or butyl-lithium is used and most preferably lithium diisopropylamide is used. Due to this po.ssible use of strong bases the benzodiazepine-alcohol of formula VI can also be present in its deprotonized form, i.e. the corresponding benzodiazepine- alcoholate is present. The solvent for this reaction should be inert to strong bases and is in particular chosen from ethers or aromatic hydrocarbons. Ethers are preferred, with the most preferable solvent being THF. Usual reaction temperatures range from -50 °C to room temperature, preferably from -30 °C to 0 °C.

The benzodiazepine of formula IV can be synthesised by reacting 3H- [1, 5] benzodiazepine-2, 4-diamine (J. Chem. Soc . , Chem. Commun. 1973, 367-368) and 1-methylpiperazine. The reaction can be carried out in a mixture of solvents comprising toluene and dimethyl sulfoxide. The reaction temperature may vary from 60°C to 180°C, preferably from 90°C to 150°C and is most preferably about 120 °C. The compounds according to formulae III to VII mentioned hereinbefore or salts thereof as well as their use for the manufacture of Olanzapine are further objects of the invention.

By the term "or salts thereof" is meant that the compound can not only be present in the form as is shown by formulae I to VII but can also be present in the form of a salt e.g. a salt formed of an organic or inorganic base and an acidic part of the compound such as the alcohol group or a salt formed of an organic or inorganic acid and a basic part of the compound such as the amino-groups . The conversion of one of the substances claimed into its salt or back into the form as is shown by formulae I to VII is within the scope of the invention. This also applies, when this conversion is performed as part of another reaction.

The invention is further illustrated with reference to the following examples .

Examples :

Example 1

Preparation of 2 , 4-bis ( -methyl-1-piperazinyl) -3H- [1, 5] benzodiazepine (IV) .

3H- [1, 5] Benzodiazepine-2,4-diamine (32.50 g, 160 mmol, 86 %) was added to a solution of dimethyl sulfoxide (220 ml) , toluene (220 ml) and 1-methylpiperazine (165 ml) . The mixture was heated for 16 h at 120 °C. After cooling the product precipitated. It was filtered off and washed with isopropyl ether (80 ml) to give 40.1 g (74 %) of the title compound as off-white needles. The second crop was obtained by adding isopropyl ether (410 ml) to the filtrate. The mixture was allowed to stand overnight at 4 °C, the crystallised product was filtered off to give additional 4.25 g (8 %) of the title compound. For analytical purposes the product was recrystallised from ethyl acetate. M.P. 227-228 °C (ethyl acetate) .

^-NMR (DMSO- e) δ = 2.21 (s, 6H) , 2.35 (m, 8H) , 3.02 (broad s,

2H) , 3.54 ( , 8H) , 6.88 (m, 2H) , 7.01 (m, 2H) .

HRMS calcd . for C19H28N6 : 340 . 2375 found : 340 . 2387 .

Example 2

Preparation of 1- [2,4-bis ( -methyl-1-piperazinyl) -3H- [l,5]benzo- diazepin-3-yl] -1-propanol (VI) .

A suspension of 2, 4-bis (4-methyl-1-piperazinyl) -3H- [1, 5] benzodiazepine (17.024 g, 50 mmol) in tetrahydrofuran (200 ml) under constant flow of argon was cooled to -30 °C. A solution of lithium diisopropylamide (LDA) (2 M, 37.5 ml, 75 mmol) was added dropwise. Thus obtained dark brown suspension was allowed to warm to -5 °C, and then again cooled to -30 °C. Propionaldehyde

(5.50 ml, 75 mmol) was added during 5 min. The resulting pale brown suspension was allowed to warm to 10 °C, while strongly agitated water (250 ml) was added. The solution was transferred to a separating funnel, chloroform (150 ml) was added and the phases were separated. The water phase was extracted with chloroform (2 x 50 ml) . The combined organic phases were dried over anhydrous Na2S04 and the solvent was evaporated at reduced pressure. The crude product was suspended in hexane (750 ml), filtered off and washed with hexane (75 ml) to give 18.34 g (92 %) of the title compound as an off-white powder. For analytical purposes the product was recrystallised from ethyl acetate.

M.P. 163-166 °C (ethyl acetete) . XH-NMR (CDC13) δ = 0.69 (t, 3H) , 1.25 (m, 2H) , 2.24 (s, 3H) , 2.30 (s, 3H) , 2.44 (m, 8H) , 3.04 (td, 1H) , 3.33 (broad s, 1H) , 3.57 (m, 8H) , 4.51 (d, 1H) , 6.98 (m, 2H) , 7.10 (m, 1H) , 7.22 (m, 1H) .

HRMS calcd. for C22H34NG0: 398.2794 found: 398.2806. Example 3

Preparation of 2,4-bis (4-methyl-1-piperazinyl) -3-propylidene-3H- [1, 5] benzodiazepine (III).

Method A

A suspension of 2 , 4-bis (4-methyl-l-piperazinyl) -3H- [1, 5] benzodiazepine (1.702 g, 5 mmol) in tetrahydrofuran (20 ml) ; under constant flow of argon was cooled to -30 °C. A solution of lith- ium diisopropylamide (LDA) (2 M, 3.75 ml, 7.5 mmol) was added dropwise. Thus obtained dark brown suspension was allowed to warm to -5 °C until dissolved and then again cooled to -30 °C. Propionaldehyd (0.54 ml, 7.5 mmol) was added during 5 min. The resulting clear yellow solution was allowed to warm to -5 °C, triethylamine (5.55 ml, 40 mmol) and pyridine (0.040 ml, 0.5 mmol) were added. A solution of trifluoroacetic anhydride (4.2 ml, 30 mmol) in tetrahydrofuran (6 ml) was added dropwise maintaining the temperature at -5 °C. The reaction mixture was stirred for another hour. Methanol (5 ml) and while strongly agitated ,NaOH (1 M, 35 ml) were added dropwise. The reaction mixture was stirred for four hours while slowly warming to room temperature . The solution was made acidic at ph of 1 and extracted with dichloromethane (3 x 25 ml) . The water phase was made alkalic at a pH of 10 and extracted with diethyl ether (15 x 25 ml) . After each extraction water phase was adjusted' to pH of 10. The ether phase was dried over anhydrous Na2S04 and ether was evaporated at reduced pressure to give 1, 701 g (89 %) of the title compound as a yellow resin.

^Η-NMR (CDC13) δ = 0.76 (t, 3H) , 1.97 (m, 2H) , 2.34 (s, 6H) , 2.45 ( , 8H) , 3.69 (m, 8H) , 5.32 (t, 1H) , 6.95 (m, 2H) , 7.16 (m, 2H) . HRMS calcd. for C22H32N6 : 380.2688 found: 380.2697.

Method B To a suspension of 1- [2 , 4-bis (4-methyl-l-piperazinyl) -3H- [1, 5] benzodiazepin-3-yl] -1-propanol (1.195 g, 3 mmol), triethylamine (2.50 ml, 18 mmol) and pyridine (0.024 ml, 0.3 mmol) in tetrahydrofuran (10 ml) under constant flow of argon, at 0 °C, a solution of trifluoroacetic anhydride (1.26 ml, 9 mmol) in tetrahydrofuran (5 ml) was added dropwise. The reaction mixture was stirred for another hour at 0 °C. Methanol (5 ml) was added. The solution was allowed to warm to 10 °C, while strongly agitated NaOH (1 M, 20 ml) was added dropwise. Dichloromethane (30 ml) was added and the phases were separated. The organic phase was dried over anhydrous Na2S04 and the solvent was evaporated at reduced pressure. The crude product was suspended in isopropyl ether (8 ml) and filtered off. The filtrate was evaporated at reduced pressure to give 0.971 g (84 %) of the title compound as a yellow resin. The product obtained was characterized using H-NMR spectroscopy and was found to be identical to the product obtained by method A.

Method C

To a suspension of 1- [2, 4-bis (4-methyl-l-piperazinyl) -3H- [1, 5] benzodiazepin-3-yl] -1-propanol (19.93 g, 50 mmol) and triethylamine (45 ml, 325 mmol) in dichloromethane (100 ml) under constant flow of argon, at 0 °C, a solution of trifluoroacetic anhydride (21 ml, 150 mmol) in dichloromethane (50 ml) was added dropwise. The reaction mixture was stirred for another hour at 0 °C. The solution was allowed to warm to room temperature. Methanol (66 ml) and tetrabutylammonium bromide (1.61 g, 5 mmol) were added successively. While strongly agi- tated NaOH (1 M, 660 ml) was added dropwise. Two phase system was agitated for two hours . The phases were separated and the water phase was extracted with dichloromethane (2 x 100 ml) . The organic phase was dried over anhydrous Na2S04 and the solvent was evaporated at reduced pressure. The crude product was suspended in isopropyl ether (150 ml) and filtered off. the filtrate was evaporated at reduced pressure to give 14.44 g (76 %) of the title compound as a brown resin.

The product obtained was characterised using H-NMR sprectrosopy and was found to be identical to the product obtained by method A. Method D

A suspension of 2, 4-bis (4-methyl-l-piperazinyl) -3H- [1, 5] benzodiazepine (45.396 g, 133.3 mmol) in tetrahydrofuran (560 ml) under constant flow of argon was cooled to -10 °C. A solution of 5 lithium diisopropylamide (LDA) (2M, 100 ml, 200 mmol) was added over a period of 20 min, maintaining the temperature at -10°C. The obtained deep red solution was stirred for 30 min. Propio- naldehyde (14.6 ml, 200 mmol) was added dropwise. Triethylamine (148 ml, 1.067 mol) and pyridine (0.54 ml, 6.7 mmol) were added

10 successively. Trifluoroacetacetic anhydride (93.1 ml, 667 mmol) was added over a period of 50 min, maintaining the temperature at -10°C. The reaction mixture was stirred for 1 h and allowed to warm to -5°C. Methanol (213 ml) and while strongly agitated NaOH (5M, 200 ml, 1.000 mol) were added maintaining the tempera-

15 ture at -5°C . The reaction mixture was allowed to warm to room temperature and stirred over night. The solution was made acidic with 5M HCI to a pH of 3.5. Two phases were formed and the lower layer was extracted with 600 ml and twice with 100 ml of dichloromethane. The aqueous phase was treated with brine (200 ml)

20 and toluene (400 ml) and made alkaline' with 5M NaOH to a pH of 10. The phases were separated and the aqueous phase was extracted with toluene (2 X 200 ml) . Combined toluene phases were dried over anhydrous Na2S04 and the solvent was evaporated at reduced pressure to give 48.38 g (95%) of the title compound

25 as an amber resin. The product obtained was characterised using H-NMR spectroscopy and was found to be identical to the product obtained by method A.

Example 4 30

Preparation of Olanzapine.

A suspension of 2, -bis (4-methyl-l-piperazinyl) -3-propylidene- 3H- [1, 5] benzodiazepine (11.90 g, 31.3 mmol), sulphur (20.07 g, 35 626 mmol) and triethyl amine (4.34 ml, 31.3 mmol) in dimethyl sulfoxide (100 ml) and 1-propanol (100 ml) was heated at 100 °C for five days. The resulting black suspension was cooled and filtered off and the filtrate was evaporated at reduced pressure to obtain a viscous black oil. Dichloromethane (600 ml) and HCI

(0.2 M, 600 ml) were added and the phases were separated. The organic phase was extracted again with HCI (0.5 M, 100 ml) . The combined water phases were made alkalic at a pH of 9 to 10. Dark brown precipitate was filtered off. Dichloromethane (250 ml) was added to the filtrate. The phases were separated and the water phase was extracted with dichloromethane (2 x 60 ml) . The organic phase was dried over anhydrous Na2S04 and the solvent was evaporated at reduced pressure. The black oil was combined with precipitate and purified by chromatography on silica gel, eluted with ethyl acetate/triethylamine 50/1 to obtain 1.195 g (12 %) of the title product .

Example 5

Preparation of Olanzapine

Method A

To a 0.118 M solution of 2, 4-bis (4-methyl-l-piperazinyl) -3-pro- pylidene-3H- [1, 5] benzodiazepine in benzonitrile (50 ml, 5.90 mmol) quinolinium p-toluenesulfonate (3.01 g, 10 mmol) and sulphur (0.64 g, 20 mmol) were added. The reaction mixture was stirred at 140°C for 13.5 h, cooled to 110°C and concentrated (78-80°C/24-30 mbar) to an oily residue. The residue was dis- solved in dichloromethane (35 ml) , water (30 ml) was added and the mixture was made acidic with 2M HCI to a pH of 0.9. The phases were separated and the aqueous phase was extracted with dichloromethane (3 X 30 ml) . The aqueous phase was made alkaline with 15 % NaOH to a pH of 7.4 and extracted with dichloromethane (2 X 30 ml) . The combined dichloromethane phases were dried over anhydrous Na2S04 and the solvent was evaporated at reduced pressure to give 1.91 g of crude Olanzapine. It contained 4.1 mmol (69.5 % yield) of Olanzapine.

Method B

To a 0.118 M solution of 2, 4-bis (4-methyl-l-piperazinyl) -3-pro- pylidene-3H- [1,5] benzodiazepine in benzonitrile (50 ml, 5.90 mmol) pyridinium p-toluenesulfonate (2.51 g, 10 mmol) and sul phur (0.64 g, 20 mmol) were added. The reaction mixture was stirred at 140°C for 13.5 h, cooled to 110°C and concentrated (78-80°C/24-30 mbar) to an oily residue. The residue was dissolved in dichloromethane (35 ml) , water (30 ml) was added and the mixture was made acidic with 2M HCI to a pH of 0.64. The phases were separated and the aqueous phase was extracted with dichloromethane (2 X 30 ml) . The dichloromethane phases were reextracted with diluted HCI (2 X 30 ml) . The combined aqueous phases were made alkaline with 15 % NaOH to a pH of 7.9 and extracted with dichloromethane (1 X 50 ml, 2 X 30 ml) . The organic phase was dried over anhydrous Na2S04. The solvent was evaporated at reduced pressure to give 1.534 g of crude Olanzapine. It contained 3.93 mmol (66.6 % yield) of Olanzapine.

Method C

To a 0.118 M solution of 2 , 4-bis (4-methyl-l-piperazinyl) -3-pro- pylidene-3H- [1, 5] benzodiazepine in benzonitrile (10 ml, 1.18 mmol) 1-methylimidazolinium p-toluenesulfonate (0.51 g, 2 mmol) and sulphur (0.128 g, 4 mmol) were added. The reaction mixture was stirred at 140°C for 10 h, then it was cooled to room temperature and left over night . The reaction mixture was heated to 110°C and concentrated (78-80°C/24-30 mbar) to an oily residue. The residue was dissolved in dichloromethane (10 ml) , water (10 ml) was added and the mixture was made acidic with 2M HCI to a pH of 0.9. The phases were separated and the aqueous phase was extracted with dichloromethane (3 X 6 ml) . The aqueous phase was made alkaline with 15 % NaOH to a pH of 8.5 and extracted with dichloromethane (6 X 6 ml) . The combined dichloromethane phases were dried over anhydrous Na2S04 and the solvent was evaporated at reduced pressure to give 0.313 g of crude Olanzapine. It contained 0.64 mmol (54.2 % yield) of Olanzapine.

Method D

To a 0.118 M solution of 2 , 4-bis (4-methyl-l-piperazinyl) -3-pro- pylidene-3H- [1, 5] benzodiazepine in benzonitrile (10 ml, 1.18 mmol) p-toluenesulfonic acid monohydrate (0.380 g, 2 mmol) and sulphur (0.128 g, 4 mmol) were added. The reaction mixture was stirred at 140°C for 9 h, cooled to 110°C and concentrated (78- 80°C/24-30 mbar) to an oily residue. The residue was dissolved in dichloromethane (15 ml) , water (10 ml) was added and the mixture was made acidic with 2M HCI to a pH of 1.0. The phases were separated and the aqueous phase was extracted with di- chloromethane (2 X 10 ml) . The dichloromethane phases were reex- tracted with diluted HCI (10 ml) . The combined aqueous phases were made alkaline with 15 % NaSO to a pH of 7.9 and extracted with dichloromethane (3 X 30 ml) . The organic phase was dried over anhydrous Na2S04. The solvent was evaporated at reduced pressure to give 0.252 g of crude Olanzapine. It contained 0.61 mmol (51.7 % yield) of Olanzapine.

Claims

Claims;
Process for the manufacture of Olanzapine of the following formula I or a salt
Figure imgf000020_0001
by converting a compound of the following formula II or a salt- thereof
in which
Figure imgf000020_0002
(i) Rl and R2 together form =CH-CH2-CH3, or
(ii) Rl and R2 are both H, or
(iii) Rl is H and R2 is -CH (R3) -CH2-CH3, wherein R3 is a' leaving group that can be eliminated together with Rl to result in Rl and R2 together forming =CH- H — CH3 ,
to give Olanzapine or a salt thereof.
2. Process according to claim 1, in which the leaving group R3 is -OR4.
3. Process according to claim 2, in which R4 is H.
4. Process according to claim 2 , in which R4 is selected from the group of acyl and sulfonyl and preferably is trifluoroacetyl or methane sulfonyl .
5. Process according to any one of claims 1 to 4, in which Rl and R2 together form =CH-CH2-CH3 and the conversion is performed by reacting the compound of formula II with a source of sulfur.
6. Propylidene-benzodiazepine of the following formula III
or salts thereof .
Figure imgf000021_0001
7 Benzodiazepine of the following formula IV:
or salts thereof.
Figure imgf000021_0002
8. Benzodiazepin-propanol of the following formula VI:
or salts thereof.
Figure imgf000021_0003
9. Benzodiazepine-ester of the following formula VII:
Figure imgf000022_0001
in which R4 is selected from the group of acyl and sulfonyl and preferably is trifluoroacetyl or methane sulfonyl, or salts thereof .
15 10. Use of a compound according to any one of claims 6 to 9 for the manufacture of Olanzapine.
20
25
30
35
PCT/EP2004/000299 2003-01-17 2004-01-16 Process and intermediates for the preparation of olanzapine WO2004065390A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE10301923.5 2003-01-17
DE2003101923 DE10301923B3 (en) 2003-01-17 2003-01-17 Processes and intermediates for the preparation of olanzapine

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SI200430996T SI1594879T1 (en) 2003-01-17 2004-01-16 Process and intermediates for the preparation of olanzapine
DE200460017281 DE602004017281D1 (en) 2003-01-17 2004-01-16 Process and intermediate products for the production of olanzapine
EP20040702675 EP1594879B1 (en) 2003-01-17 2004-01-16 Process and intermediates for the preparation of olanzapine
US10/541,604 US7498433B2 (en) 2003-01-17 2004-01-16 Process and intermediates for the preparation of olanzapine
EA200501137A EA007950B1 (en) 2003-01-17 2004-01-16 The process and intermediates for the preparation of olanzapine
YUP-2005/0543A RS51033B (en) 2003-01-17 2004-01-16 Process and intermediates for the preparation of olanzapine
NO20053829A NO331720B1 (en) 2003-01-17 2005-08-15 The process feed and intermediates for the preparation of olanzapine.

Publications (2)

Publication Number Publication Date
WO2004065390A1 true WO2004065390A1 (en) 2004-08-05
WO2004065390A8 WO2004065390A8 (en) 2004-12-16

Family

ID=32747459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000299 WO2004065390A1 (en) 2003-01-17 2004-01-16 Process and intermediates for the preparation of olanzapine

Country Status (11)

Country Link
US (1) US7498433B2 (en)
EP (1) EP1594879B1 (en)
AT (1) AT411999T (en)
DE (2) DE10301923B3 (en)
EA (1) EA007950B1 (en)
ES (1) ES2316955T3 (en)
NO (1) NO331720B1 (en)
PT (1) PT1594879E (en)
RS (1) RS51033B (en)
SI (1) SI1594879T1 (en)
WO (1) WO2004065390A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063771A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries Ltd Methods of preparing olanzapine
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1533235A (en) * 1974-11-26 1978-11-22 Lilly Industries Ltd Benzodiazepine derivatives
EP0454436A1 (en) * 1990-04-25 1991-10-30 Lilly Industries Limited Pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1533235A (en) * 1974-11-26 1978-11-22 Lilly Industries Ltd Benzodiazepine derivatives
EP0454436A1 (en) * 1990-04-25 1991-10-30 Lilly Industries Limited Pharmaceutical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CALLIGARO, D.O. ET AL.: "The Synthesis and Biological Activity of some known and Putative Metabolites of the Atypical Antipsychotic Agent Olanzapine (LY170053)", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 1, 1997, pages 25 - 30, XP002279427 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
WO2005063771A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries Ltd Methods of preparing olanzapine
US7425627B2 (en) 2003-12-22 2008-09-16 Teva Pharmaceutical Industries Ltd. Methods of synthesizing olanzapine

Also Published As

Publication number Publication date
NO20053829L (en) 2005-10-12
RS20050543A (en) 2007-06-04
ES2316955T3 (en) 2009-04-16
WO2004065390A8 (en) 2004-12-16
US7498433B2 (en) 2009-03-03
SI1594879T1 (en) 2009-04-30
DE602004017281D1 (en) 2008-12-04
NO331720B1 (en) 2012-03-05
EA200501137A1 (en) 2006-02-24
AT411999T (en) 2008-11-15
DE10301923B3 (en) 2004-09-16
RS51033B (en) 2010-10-31
EA007950B1 (en) 2007-02-27
NO20053829D0 (en) 2005-08-15
EP1594879A1 (en) 2005-11-16
EP1594879B1 (en) 2008-10-22
PT1594879E (en) 2008-11-14
US20060040921A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
US3400128A (en) Heterocyclic intermediates
KR100242398B1 (en) Condensed imidazopyridine derivatives
US3853915A (en) 9-or 10-halo-4h-benzo{8 4,5{9 cyclo-hepta{8 1,2-b{9 thiophen-4-ones
CA1076571A (en) Tetracyclic derivatives of benzo-pyrido azepines
AU645504B2 (en) Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient
AU2003265585B2 (en) Calcium receptor modulating compound and use thereof
US4690930A (en) Pyrazolo[4,3-c]quinoline-3-one and imidazo[4,3-c]cinnolin-3-one derivatives and their use as psychotropic agents
KR101214394B1 (en) Method for the production of dihydropteridinones
Vega et al. Synthesis of 3‐substituted‐4‐phenyl‐2‐thioxo‐1, 2, 3, 4, 5, 6, 7, 8‐octahydrobenzo [4, 5] thieno [2, 3‐á] pyrimidines
EP0230942B1 (en) Thieno-1,4-diazepines
PT86120B (en) Process for the preparation of n9-cyclopentil-adenin derivatives
DK171967B1 (en) Quinolinecarboxylic acid derivatives, process for the preparation thereof, and a pharmaceutical agent containing the same
US4777253A (en) Process for preparation of racemate and optically active ofloxacin and related derivatives
HU215957B (en) New procedure tetrahydro-thieno [3,2-c] pyridine N-phenyl-acetic acid derivatives for preparing the dextrorotatory isomer of
EP1077927A1 (en) Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
KR900007780B1 (en) Process for preparing condensed pyrrolinone derivatives
AU6851598A (en) Tricyclic compounds
JPH0662574B2 (en) Substituted benzazepine, their preparation and pharmaceutical compositions containing them
EP0254245A1 (en) Hetrazepins and processes for their preparation
AU2004267061A1 (en) Process for the preparation of 4-amino-3-quinolinecarbonitriles
FR2525595A1 (en) Novel arene and heteroarenecarboxamide derivatives and their use as medicaments
CZ2003566A3 (en) Process for preparing olanzapin hydrates and their conversion to olanzapin crystal forms
DD283394A5 (en) Method for the production of indilocarbazol derivatives
CA1273632A (en) Cyclopenta(d)pyrimidine derivatives their preparation and use
CA2196263C (en) Process for the preparation of 4-oxoimidazolinium salts

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0543

Country of ref document: YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 32/2004 UNDER (72, 75) ADD "ZUPET, ROK ¢SI/SI!; JANEZA ROZICA 6, 1211 LJUBLJANA (SI). BENEDIK, MILENA ¢SI/SI!; RATEZ 12, 8321 BRUSNICE (SI)."

CFP Corrected version of a pamphlet front page
ENP Entry into the national phase in:

Ref document number: 2006040921

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10541604

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004702675

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200501137

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004702675

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10541604

Country of ref document: US